Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad

Current strategies to treat type 2 diabetes (DMT2) include reducing insulin resistance using glitazones, supplementing with exogenous insulin, increasing endogenous insulin production with sulfonylureas and meglitinides, reducing hepatic glucose production through biguanides, and limiting postprandi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bastarrachea,Raúl A, Montero,Julio C, Saavedra-Gajardo,íctor, Cerda-Flores,Ricardo, Machado-Domínguez,Anselmo, Comuzzie,Anthony G
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2008
Materias:	Diabetes, type 2 Obesity Pharmacogenetics
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872008000100014
record_format	dspace
spelling	oai:scielo:S0034-988720080001000142008-04-30Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidadBastarrachea,Raúl AMontero,Julio CSaavedra-Gajardo,íctorCerda-Flores,RicardoMachado-Domínguez,AnselmoComuzzie,Anthony G Diabetes, type 2 Obesity Pharmacogenetics Current strategies to treat type 2 diabetes (DMT2) include reducing insulin resistance using glitazones, supplementing with exogenous insulin, increasing endogenous insulin production with sulfonylureas and meglitinides, reducing hepatic glucose production through biguanides, and limiting postprandial glucose absorption with alpha-glucosidase inhibitors. In all of these areas, new generations of molecules with improved efficacy and safety profiles, are being investigated. Promising biological targets are rapidly emerging such as the role of lipotoxicity as a cause of glucometabolic insulin resistance, leading to a host of new molecular drug targets such as AMP-activated protein kinase (AMPK) activators, recombinant adiponectin derivatives, and fatty acid synthase (FAS) inhibitors. Insulin action can be enhanced in muscle, liver and fat, with small-molecule activators of the insulin receptor or inhibitors of protein tyrosine phosphatase (FTP)-IB. Defective glucose-stimulated insulin secretion by pancreatic B-cells could be alleviated with recombinant glucagon-like peptide (GLP-1) or agonists to the GLP-1 receptor. This review presents a new approach for obesity and DMT2 drug discovery through pharmacogenomics. Several compounds have already been validated through genetic engineering in animal models or the preliminary use of therapeutic compounds in humans (Rev Méd Chile 2008; 136:107-17)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.136 n.1 20082008-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100014es10.4067/S0034-98872008000100014
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Diabetes, type 2 Obesity Pharmacogenetics
spellingShingle	Diabetes, type 2 Obesity Pharmacogenetics Bastarrachea,Raúl A Montero,Julio C Saavedra-Gajardo,íctor Cerda-Flores,Ricardo Machado-Domínguez,Anselmo Comuzzie,Anthony G Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
description	Current strategies to treat type 2 diabetes (DMT2) include reducing insulin resistance using glitazones, supplementing with exogenous insulin, increasing endogenous insulin production with sulfonylureas and meglitinides, reducing hepatic glucose production through biguanides, and limiting postprandial glucose absorption with alpha-glucosidase inhibitors. In all of these areas, new generations of molecules with improved efficacy and safety profiles, are being investigated. Promising biological targets are rapidly emerging such as the role of lipotoxicity as a cause of glucometabolic insulin resistance, leading to a host of new molecular drug targets such as AMP-activated protein kinase (AMPK) activators, recombinant adiponectin derivatives, and fatty acid synthase (FAS) inhibitors. Insulin action can be enhanced in muscle, liver and fat, with small-molecule activators of the insulin receptor or inhibitors of protein tyrosine phosphatase (FTP)-IB. Defective glucose-stimulated insulin secretion by pancreatic B-cells could be alleviated with recombinant glucagon-like peptide (GLP-1) or agonists to the GLP-1 receptor. This review presents a new approach for obesity and DMT2 drug discovery through pharmacogenomics. Several compounds have already been validated through genetic engineering in animal models or the preliminary use of therapeutic compounds in humans (Rev Méd Chile 2008; 136:107-17)
author	Bastarrachea,Raúl A Montero,Julio C Saavedra-Gajardo,íctor Cerda-Flores,Ricardo Machado-Domínguez,Anselmo Comuzzie,Anthony G
author_facet	Bastarrachea,Raúl A Montero,Julio C Saavedra-Gajardo,íctor Cerda-Flores,Ricardo Machado-Domínguez,Anselmo Comuzzie,Anthony G
author_sort	Bastarrachea,Raúl A
title	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
title_short	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
title_full	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
title_fullStr	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
title_full_unstemmed	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
title_sort	objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad
publisher	Sociedad Médica de Santiago
publishDate	2008
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100014
work_keys_str_mv	AT bastarrachearaula objetivosmolecularesparadisenarnuevosfarmacosparaeltratamientodeladiabetestipo2ylaobesidad AT monterojulioc objetivosmolecularesparadisenarnuevosfarmacosparaeltratamientodeladiabetestipo2ylaobesidad AT saavedragajardoictor objetivosmolecularesparadisenarnuevosfarmacosparaeltratamientodeladiabetestipo2ylaobesidad AT cerdafloresricardo objetivosmolecularesparadisenarnuevosfarmacosparaeltratamientodeladiabetestipo2ylaobesidad AT machadodominguezanselmo objetivosmolecularesparadisenarnuevosfarmacosparaeltratamientodeladiabetestipo2ylaobesidad AT comuzzieanthonyg objetivosmolecularesparadisenarnuevosfarmacosparaeltratamientodeladiabetestipo2ylaobesidad
_version_	1718436359219183616

Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad

Ejemplares similares